KCT0003865尚未招募未知
A randomized, Double blinded, Placebo-Controlled, Researcher clinical Study to Evaluate the Efficacy and the Safety of Oryung-san Extract Granules in Stage 1 Hypertension Patients without Antihypertensive Medication
Woosuk University Korean Medicine Medical Center0 个研究点目标入组 72 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) Aged = 19 years old
- •2) Before Randomized, if either of the following applies
- •- 140 mmHg =MSSBP < 159 mmHg
- •- 90 mmHg = MSDBP < 99 mmHg
- •3) Those who are not currently taking anti-hypertensive medication and who have not taken medication for hypertension within the last 4 weeks
- •4) Those who have the ability and willingness to voluntarily agree to take part in the clinical trial and participate in the test
排除标准
- •1) At screening and randomized, MSSBP = 160 mmHg or MSDBP = 100 mmHg
- •2) At screening, SSBP difference is = 20 mmHg and SDBP difference= 10mmHg
- •3) Known or suspected secondary hypertension(ex. aortic coarctation, hyperaldosteronism, renal artery stenosis, Cushing's syndrome, pheochromocytoma, polycystic kidney disease)
- •4) Patients with orthostatic hypotension with symptoms
- •5) Unregulated diabetes (Excluding patients who do not need diabetes medication during the study period)
- •6) Patients with severe heart disease, ischemic heart disease within 6months, peripheral vascular disease, Percutaneous Transluminal Coronary Angiography (PTCA), Coronary Artery Bypass Graft (CABG)
- •7) Patients with significant ventricular tachycardia, atrial fibrillation, atrial flutter or other significant arrhythmia
- •8) Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, immunologically significant aortic or mitral stenosis
- •9) Subject with severe cerebrovascular disease (infarct, hemorrage) ithin recent 6 months.
- •10) known severe or malignant retinopathy(retinal hemorrhage, visual disturbance, Retinal microaneurysms and so on within 6 months)
- •11) Patients with wasting disease, autoimmune disease, connective tissue disease at present and/or previous
- •12) There is clinically significant kidney or liver disease defined by the following laboratory parameters:
- •- renal dysfunction(CCr < 30 mL/min, Serum creatinine = 2 mg/dL or UNL X 1.5)
- •- hepatic dysfunction(AST/ALT = UNL X 3)
- •13) Patients with surgical and medical disease it is able to be affect to absorption, distribution, metabolism, excretion
- •14) Patients who are dependent on drugs or alcohol
- •15) Childbearing and breast-feeding women, A female patient whose pregnancy was confirmed by a pregnancy test of urine specimen. Female who plan to become pregnancy or have a possibility of pregnancy but don't prevent conception with acknowledged methods
- •16) chronic inflammatory status need to treatment
- •17) Persons with known or suspected hypersensitivity reactions to the test substance or the same class of drug
- •18) Those who participated in other studies within 3 months before screening.
- •19) Those who drank on the day of study participation, those who consumed caffeine drinks within 1 hour
- •20) Subject who the opinion investigator make a judgment to be unsuitable for any other reason
研究者
相似试验
进行中（未招募）
1 期
A study to investigate the effects of Broncho-Vaxom (OM-85 BV) on the immune system in patients with Chronic obstructive pulmonary diseaseEUCTR2013-001940-71-GBOM Pharma SA
已完成
不适用
A Clinical Study to Evaluate the Safety and Efficacy of CurQlife 500 mg and CurQlife P 500 mg (Curcumin based formulation) in Reducing Symptoms of Knee Osteoarthritis.CTRI/2013/12/004266aila Pharmaceuticals Pvt Ltd60
已完成
Unknown
A Clinical study to understand the safety and effectivesness of a new product on adult males and females having joint pain.CTRI/2023/09/057317GIELLEPI S.p.A90
已完成
不适用
A Clinical Study to Evaluate the Efficacy of Herbal Extract on Immune Health in Healthy Adult VolunteersCTRI/2014/12/005247ITC Limited70
已完成
2 期
Effect of Kutki as animmune booster in adult and elderly population.CTRI/2021/08/035738InnAdapt Immune60